$414 Million is the total value of Endurant Capital Management LP's 68 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IVC | Exit | INVACARE CORP | $0 | – | -1,146,068 | -100.0% | -0.07% | – |
| CYAD | Exit | CELYAD ONCOLOGY SAadr | $0 | – | -145,380 | -100.0% | -0.14% | – |
| PDCO | Exit | PATTERSON COS INC | $0 | – | -26,799 | -100.0% | -0.18% | – |
| XENE | Exit | XENON PHARMACEUTICALS INC | $0 | – | -62,743 | -100.0% | -0.22% | – |
| ALVR | Exit | ALLOVIR INC | $0 | – | -44,430 | -100.0% | -0.25% | – |
| BOLT | Exit | BOLT BIOTHERAPEUTICS INC | $0 | – | -90,041 | -100.0% | -0.26% | – |
| KRYS | Exit | KRYSTAL BIOTECH INC | $0 | – | -22,938 | -100.0% | -0.27% | – |
| ACRS | Exit | ACLARIS THERAPEUTICS INC | $0 | – | -67,300 | -100.0% | -0.28% | – |
| MRVI | Exit | MARAVAI LIFESCIENCES HLDGS I | $0 | – | -29,838 | -100.0% | -0.33% | – |
| MREO | Exit | MEREO BIOPHARMA GROUP PLCads | $0 | – | -746,514 | -100.0% | -0.41% | – |
| BLU | Exit | BELLUS HEALTH INC NEW | $0 | – | -389,833 | -100.0% | -0.54% | – |
| RGLS | Exit | REGULUS THERAPEUTICS INC | $0 | – | -3,547,208 | -100.0% | -0.56% | – |
| ATR | Exit | APTARGROUP INC | $0 | – | -51,191 | -100.0% | -1.39% | – |
| Exit | INVACARE CORPnote 5.000%11/1 | $0 | – | -7,000,000 | -100.0% | -1.41% | – | |
| MCK | Exit | MCKESSON CORP | $0 | – | -32,551 | -100.0% | -1.48% | – |
| ICLR | Exit | ICON PLC | $0 | – | -46,720 | -100.0% | -2.79% | – |
| BMY | Exit | BRISTOL-MYERS SQUIBB CO | $0 | – | -211,821 | -100.0% | -2.85% | – |
| ABBV | Exit | ABBVIE INC | $0 | – | -180,429 | -100.0% | -4.43% | – |
| Exit | TRILLIUM THERAPEUTICS INCcall | $0 | – | -206,800 | -100.0% | -8.27% | – | |
| Exit | INVACARE CORPnote 5.000%11/1 | $0 | – | -56,727,000 | -100.0% | -11.66% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| LABORATORY CORP AMER HLDGS | 31 | Q2 2023 | 8.7% |
| ELEVANCE HEALTH INC | 29 | Q3 2023 | 8.8% |
| BECTON DICKINSON & CO | 28 | Q2 2023 | 9.8% |
| MCKESSON CORP | 27 | Q1 2023 | 4.4% |
| CENCORA INC | 26 | Q3 2023 | 5.9% |
| HOLOGIC INC | 24 | Q3 2023 | 7.5% |
| JOHNSON & JOHNSON | 24 | Q4 2021 | 5.5% |
| ZIMMER HLDGS INC | 23 | Q3 2023 | 7.5% |
| BOSTON SCIENTIFIC CORP | 22 | Q3 2023 | 5.5% |
| DAVITA INC | 22 | Q1 2021 | 4.9% |
View Endurant Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| AZIYO BIOLOGICS, INC. | March 21, 2023 | 576,253 | 4.9% |
| Oxford Immunotec Global PLCSold out | February 17, 2021 | 0 | 0.0% |
View Endurant Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-07 |
| SC 13D/A | 2024-04-10 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13D/A | 2023-09-08 |
| 13F-HR | 2023-08-14 |
| 3/A | 2023-05-24 |
| 13F-HR | 2023-05-15 |
| 3 | 2023-05-15 |
| SC 13D | 2023-05-15 |
View Endurant Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.